Pharmaron Beijing Co., Ltd. (Pharmaron) has approved two major proposals aimed at strengthening its long-term incentive structure and aligning corporate governance with the latest regulatory standards.

Key Takeaways

1. Launch of 2026 H-Share Award and Trust Scheme • Scope: Up to 28.00 million H shares, to be sourced from a mix of repurchased treasury shares and newly issued shares. • Tenure: Valid for 10 years from the date of shareholder approval. • Objective: Enhance employee motivation, bolster core-team cohesion and support sustained, high-quality growth. • Compliance: Designed to meet the requirements of Chapter 17 of the Hong Kong Listing Rules. • Next Steps: Board will seek shareholder authorisation for a share-repurchase mandate and delegation of scheme administration at the forthcoming general meeting.

2. Amendments to the Articles of Association • Alignment: Updates incorporate the 2025 Guidelines on Articles of Association of Listed Companies and the 2026 revision of the ChiNext Listing Rules. • Key Changes: – Standardised wording in line with current regulations. – Explicit provisions on guarantee arrangements, connected-transactions oversight and identification of actual controllers. – Removal or revision of clauses rendered obsolete by updated rules. • Procedure: Amendments require approval by special resolution at the general meeting and subsequent regulatory filings; current articles remain effective until completion.

3. Shareholder Communication A detailed circular outlining the 2026 H-Share Scheme and the proposed Articles amendments, together with the notice of the general meeting, will be dispatched to shareholders in due course.

Leadership Statement The announcement was authorised by Chairman Dr. Lou Boliang following a Board meeting held in Beijing on 24 July 2026.